Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens
Author:
Publisher
Springer Science and Business Media LLC
Link
https://link.springer.com/content/pdf/10.1007/s10549-023-07236-z.pdf
Reference20 articles.
1. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA et al (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 106(5):dju055. https://doi.org/10.1093/jnci/dju055
2. Loibl S, Gianni L (2017) HER2-positive breast cancer. Lancet 389(10087):2415–2429. https://doi.org/10.1016/S0140-6736(16)32417-5
3. Smith AE, Ferraro E, Safonov A, Morales CB, Lahuerta EJA, Li Q et al (2021) HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway. Nat Commun 12(1):6667. https://doi.org/10.1038/s41467-021-27093-y
4. Smyth LM, Piha-Paul SA, Won HH, Schram AM, Saura C, Loi S et al (2020) Efficacy and determinants of response to HER kinase inhibition in HER2-mutant metastatic breast cancer. Cancer Discov 10(2):198–213. https://doi.org/10.1158/2159-8290.CD-19-0966
5. Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N et al (2018) The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell. 34(3):427–38 e6. https://doi.org/10.1016/j.ccell.2018.08.008
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3